Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 November 2021 | Story Andrè Damons
Prof Motlalepula Matsabisa
Good news galore. Prof Motlalepula Matsabisa, Professor and Director of Pharmacology at the University of the Free State (UFS), received more good news recently when he was awarded a Visiting Professorship at the Beijing University of Chinese Medicine (BUCM) in Beijing, China, as well as being elected as the Deputy President of the South African Society for Basic and Clinical Pharmacology. Prof Matsabisa was also recommended by Dr Blade Nzimande, Minister of Higher Education, Science and Technology, part of the IBSA technical committee.

Prof Motlalepula Matsabisa, Professor and Director of Pharmacology at the University of the Free State (UFS), received more good news recently when he was awarded a Visiting Professorship at the Beijing University of Chinese Medicine (BUCM) in Beijing, China. This news comes at the same time as the traditional medicine expert has been elected as the Deputy President of the South African Society for Basic and Clinical Pharmacology.

This is, however, not the end of the good news for Prof Matsabisa. Dr Blade Nzimande, Minister of Higher Education, Science and Technology, recommended him to Naledi Pandor, Minister of International Relations and Cooperation, to be part of the India, Brazil and South Africa (IBSA) working group in traditional medicine. As a member of the Department of Science and Innovation (DSI) Indigenous Knowledge-based Bio-Innovation programme, Prof Matsabisa, together with Prof Nceba Gqaleni, is part of the IBSA technical committee. Prof Matsabisa is also part of a technical team for National Department of Health on traditional medicines for the IBSA countries 

Unexpected honours

“I was not expecting any of these honours. It comes as a total shock. To have gone through the stringent evaluation and selection process at the BUCM and made it to the university’s highest award, is an honour. This is recognition of my academic and research quality by my peers on an international level.

“Being elected to lead a society of researchers and clinicians in the field of Pharmacology in the country is further recognition nationally of the academic and research excellence status. These awards coming at the same time is unbelievable. I am proud of the work I do as well as a gesture of support from scientists nationally and internationally and the support from UFS having allowed me to do what I do best academically,” says Prof Matsabisa.

According to him, some of the key expectations for this Visiting Professorship at the BUCM are teaching, to do collaborative research and conduct workshops jointly as well as joint leverage of research funding and co-publications. Prof Matsabisa will now, together with his counterparts at BUCM, discuss and synchronise their teaching and research so they plan the visit to benefit the UFS and the BUCM.

The South African Society for Basic and Clinical Pharmacology’s main activities are to bring pharmacologists together and share new scientific knowledge and developments in the field, explains Prof Matsabisa. The Society is for teaching and training; including research in both basic and clinical pharmacology, to support pharmacology conferences nationally and continentally. “We develop young pharmacologists and are also affiliated to international pharmacology societies. The purpose of the South African Society for Basic and Clinical Pharmacology is to excel and grow the pharmacology field in medicine.”

A good year for pharmacology and the UFS

This has been a good year for him and the team, for pharmacology and the UFS, says Prof Matsabisa. Most recently, Prof Matsabisa and the Department of Pharmacology received a grant of R58 million to establish one of the most advanced modern Pharmacology GLP-accredited research and development laboratories in the country, and possibly in the region. The department has also been awarded an annual Technology and Innovation Agency Platform (TIA) grant of R17 million for the next five years early this year.

“I am able to do what I do and achieve all this because of teamwork. I have a value chain of teams from support staff, cleaners, security, technical and research scientists with me. I have good students, postdoctoral fellows as well as management behind me.

“I hope such an environment can be given to all researchers to do what they do best and be supported fully and genuinely by senior management with decisions that are favourable to growing the institution without any favouritism or prejudice to anyone. It has indeed been a good year with all the funding we received. Watch this space for more.”

Looking forward most to China

Prof Matsabisa says he is looking forward to taking some of his postgraduate students with him to spend time at BUCM for training and conducting research. Says Prof Matsabisa: “I have very good postgraduate research students that need all the support. I look forward to spending a month or so at BUCM teaching BUCM students. I will leave my students there in good hands for 6-12 months per year. I promise, when these students return, they will return with a positive attitude for research and accountability.”

This was the case for him when he got a British scholarship to spend time at GlaxoSmithKline and the University of Bradford in the UK for his PhD. 

Prof Matsabisa hopes to use this Professorship at BUCM to popularise the work of the UFS and to create opportunities for new and upcoming researchers in the field of Pharmacology of Medicinal plants. This is his development plan

News Archive

HIV Cure – Just another fantasy?
2016-07-27

Description: HIV Cure – Just another fantasy? Tags: HIV Cure – Just another fantasy?

Dr Dominique Goedhals, Prof John Frater,
Dr Thabiso Mofokeng and Dr Jacob Jansen van Vuuren,
attended the lecture. Prof Frater has been working in
collaboration with the UFS Department of Internal
Medicine on HIV resistance and HIV immunology
since 2007.

Photo: Nonsindiso Qwabe

Twenty-years ago, after a person had been diagnosed with HIV, their lifespan did not exceed three years, but thanks to the success of antiretroviral therapy programmes, life expectancy has risen by an average of ten years. However, is antiretroviral therapy always going to be for life? This is the societal issue that Professor John Frater, addressed in his talk at the University of the Free State. He is an MRC Senior Clinical Fellow, Associate Professor and Honorary Consultant Physician in Infectious Diseases at  Oxford University.

Antiretroviral medicine therapeutic

The discovery of antiretroviral therapy - the use of HIV medicines to treat the virus - has had a positive effect on the health and well-being of people living with it, improving their quality of life. Unfortunately, if treatment is stopped, HIV rebounds to the detriment of the patient. Now, research has shown that some patients, who are treated soon after being infected by HIV, may go off treatment for prolonged periods. Work is being done to predict who will be able to stop treatment.

“The difference made by starting treatment earlier is enormous. Delaying treatment is denying yourself the right to health,” Professor Frater says. However, this does not mean that the virus is cured. “A person can live for ten years without being on HIV treatment, but is that enough?” he went on to ask.

Healthy lifestyles encouraged

The National Department of Health will adopt a test and treat immediately strategy later this year to improve patient health and curb the spread of HIV. ,This is another reason why everybody should know their status and start treatment as soon as possible.

Search for a cure continues

More research is being conducted to establish whether HIV can be eradicated. Remission gives hope that a permanent cure may be found eventually. “Will a cure for HIV ever be found? Time will tell,” he concluded.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept